References
- 1. SENTÍM, ROMERO R, PEDRO-BOTET J, PELEGRÍA, NOGUÉS X, RUBIÉS-PRAT J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int. 1992; 41:1394.
- 2. ATTMAN PO, SAMUELSSON O, ALAUPOVIC P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993; 21:573.
- 3. ARNADOTTIR M, THYSELL H, DALLONGEVILLE J, FRUCHART JC, NILSSON-EHLE P. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int. 1995; 48:779.
- 4. LACOUR B, ROULLET JB, LIAGRE AM, JORGETTI V, BEYNE P, DUBOST C, DRÜEKE T. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis. 1986; 8:422.
- 5. LIANG K, OVEISI F, VAZIRI ND. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int. 1998; 53:626.
- 6. AKMAL M, PERKINS S, KASIM SE, OH HY, SMOGORZEWSKI M, MASSRY SG. Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. Am J Kidney Dis. 1993; 22:158.
- 7. CHEUNG AK, PARKER CJ, REN K, IVERIUS PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int. 1996; 49:1360.
- 8. KRIS-ETHERTON PM, HARRIS WS, APPEL LJ, et al. American Heart Association, Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002; 106:2747-2757.
- 9. SERHAN CN, HONG S, GRONERT K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med.2002;196: 1025-1037.
- 10. HARRIS WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin. Nutr. 1997; 65:1645S-1654S.
- 11. ERITSLAND J, ARNESEN H, GRONSETH K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol. 1996; 77:31-36.
- 12. THIES F, GARRY JM, YAQOOB P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet. 2003; 361:477-485.
- 13. FRIEDMAN AN, MOE SM, PERKINS SM, et al. Fish consumption and omega-3 fatty acid status and determinants in longterm hemodialysis. J Am Kidney Dis 2006:1064-1071.
- 14. FRIEDMAN AN, SIDDIQUI R, WATKINS BA. Acute rise of omega-3 polyunsaturated fatty acids during hemodialysis treatment. J Ren Nutr 2008; 18(3):301-3.
- 15. OMRANI HR, PASDAR Y, RAISI D, NAJAFI F, ESFANDIARI A. The effect of omega-3 on serum lipid profile in hemodialysis patients. J Renal Inj Prev. 2015; 4:68-72.
- 16. TAZIKI O, LESSAN-PEZESHKI M, AKHA O, VASHEGHANI F. The effect of low dose omega-3 on plasma lipids in hemodialysis patients. Saudi J Kidney Dis Transpl. 2007; 18(4):571-6.
- 17. HASSAN KS, HASSAN SK, HIJAZI EG, KHAZIM KO. Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients. Ren Fail. 2010; 32:1031-5.
- 18. BAYS HE, TIGHE AP, SADOVSKY R, DAVIDSON MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc. Ther. 2008; 6:391-409.
- 19. HARRIS WS. N-3 Fatty acids and serum lipoproteins: human studies. Am J Clin. Nutr 1997; 65:S1645-54.
- 20. LAPUZ M, AVRAM MM, LUSTIG A, GOLDWASSER P, ANTIGNANI A, FEIN PA, et al. Fall of cholesterol with time on dialysis: impact on atherogenicity. ASAIO Trans. 1989; 35:258-60.
- 21. CHI H, LIN X, HUANG H, ZHENG X, LI T, ZOU Y. Omega-3 fatty acid supplementation on lipid profiles in dialysis patients: meta-analysis. Arch Med Res. 2014; 45:469-77.
- 22. ASHTIYANI SC, NAJAFI H, KABIRINIA K, VAHEDI E, JAMEBOZORKYL. Oral omega-3 fatty acid for reduction of kidney dysfunction induced by reperfusion injury in rats. Iran J Kidney Dis. 2012; 6:275-83.
- 23. HOLM T, ANDREASSEN AK, AUKRUST P, ANDERSEN K, GEIRAN OR, KJEKSHUS J, et al. Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J. 2001; 22:428-36.